CN103948458A - Encephalic drug eluting stent - Google Patents
Encephalic drug eluting stent Download PDFInfo
- Publication number
- CN103948458A CN103948458A CN201410184710.4A CN201410184710A CN103948458A CN 103948458 A CN103948458 A CN 103948458A CN 201410184710 A CN201410184710 A CN 201410184710A CN 103948458 A CN103948458 A CN 103948458A
- Authority
- CN
- China
- Prior art keywords
- drug
- stent
- encephalic
- drug eluting
- intracranial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses an encephalic drug eluting stent in the field of medicines, and particularly relates to the drug eluting stent used for curing the encephalic atherosclerotic stenosis disease. Diseased blood vessels are expanded by the stent to improve the condition of stenosis, so as to improve the blood flow state, meanwhile, drug carried by the stent can be used for preventing a tunica elastica interna from hyperplasia, and the probability of in-stent restenosis can be lowered. The encephalic drug eluting stent comprises a conveying system, a stent body and a stent drug carrying layer, and is characterized in that one or more drug carrying layers are attached to the surface of the encephalic drug eluting stent; each drug carrying layer is composed of a polymer and an active ingredient, the active ingredient is an antiplatelet drug cilostazol, and each drug carrying layer comprises the following components by weight percent: 5 to 50 percent of the polymer and the balance of active ingredients; the active ingredients in all medicine carrying layers are the same or different. The encephalic drug eluting stent provided by the invention has the advantages that the functions of protecting blood vessels, restraining inflammation reactions, expanding blood vessels and the like can be achieved, and the purpose of preventing encephalic vascular in-stent restenosis can be achieved.
Description
Technical field
The present invention relates to a kind of intracranial bracket for eluting medicament of field of medicaments, specifically, that one is used for the treatment of Intracranial atherosclerotic stenosis disease (intracranial atherosclerotic stenosis, ICS) bracket for eluting medicament, expand lesion vessels by support, improve narrow situation, thereby improve blood flow state, the medicine that support carries simultaneously can prevent tunica intima hyperplasia, reduces the probability of in-stent restenosis.
Background technology
Intracranial atherosclerotic stenosis disease (intracranial atherosclerotic stenosis, ICS) is the major reason of Ischemic Stroke.There are some researches show, 1 year apoplexy recurrence rate of severe ICS patient (stenosis rate 70%-90%) is up to 23%.The treatment that intracranial artery support is narrow mainly comprises Drug therapy, Surgery and surgical intervention.Surgical operation therapy is due to its high case fatality rate, and high disability rate and high-tech requirement, seriously limited its clinical practice.Surgery has comprised simple balloon dilatation and intravascular stenting.Interventional therapy method, because its wound is little, recovers fast, and its application is progressively popularized.One of stent endoprosthesis shortcoming is in-stent restenosis, and stent restenosis rate can be up to 53%.The reason of stent restenosis is that blood vessel causes blood vessel injury after support expansion, thereby causes tunica intima hyperplasia, finally causes the restenosis of blood vessel.
The bracket for eluting medicament of open report, all should be used for the treatment of cardiovascular atherosclerotic stenosis disease at present.For the problem that how to solve intracranial vessel stent restenosis, the present invention discloses a kind of intracranial bracket for eluting medicament technology.
Summary of the invention
In order to solve above-mentioned stent restenosis problem, the object of this invention is to provide a kind of intracranial bracket for eluting medicament, there is following characteristics: formed by support and medicine.Support is opened after arriving lesion locations, and to reach the object of dredging narrow blood vessel, the medicine that support carries simultaneously, effectively prevents tunica intima hyperplasia, thereby prevent stent restenosis.
To achieve the above object, the present invention has adopted following technical scheme:
A kind of intracranial bracket for eluting medicament, comprise induction system, support and support drug-loaded layer, stent delivery system and conventional sacculus stent delivery system or similar from exapnsion cribbing induction system, the object of induction system is for carrying described support to arrive lesion locations and discharging smoothly described support.Described support and conventional ball expand support or self-expandable stent similar, the object of described support, for being positioned in lesion vessels, reaches the object of dredging narrow blood vessel.Described intracranial bracket for eluting medicament surface is with drug-loaded layer, drug-loaded layer is made up of polymer and active component, described active component is antiplatelet drug cilostazol, cilostazol is a kind of medicament for resisting platelet aggregation, by suppressing phosphodiesterase 3, thereby the concentration of increase cyclic adenosine monophosphate reaches the effect of anticoagulant.Cilostazol not only has antiplatelet effect, also has vasorelaxation action, and the inhibitory action of vascular smooth muscle cell growth, suppresses thrombosis, protection blood vessel wall and the effect of endotheliocyte and the effect of neuroprotective.Clinical research shows, after angiocarpy sacculus expansion intervene operation, cilostazol group vascular restenosis rate is starkly lower than aspirin group.CREST(Coronary Stent Restenosis in Patients Treated WithCilostazol, the Cilostazol for Restenosis Trial) clinical research shows after stenting, the vascular restenosis rate of cilostazol group is not significantly lower than containing cilostazol group.CSPS (Cilostazol Stroke Prevention Study) clinical research shows, cilostazol is compared with placebo, can significantly reduce the relative risk of cerebral infarction recurrence.Relevant clinical research shows simultaneously, and compared with aspirin, cilostazol significantly reduces hemorrhagic apoplexy, myocardial infarction, and vascular death and overall hemorrhagic event, and may reduce gastrointestinal hemorrhage in the secondary prevention of apoplexy.Effectiveness and the safety of the field clinical practice of cilostazol neural blood vessel are fully verified; Described polymer is ethylene-vinyl alcohol copolymer or vinyl-vinyl acetate copolymer or styrene-isobutylene block copolymer.
The weight proportion of drug-loaded layer: polymer is 5-50%, all the other are active component; Described drug-loaded layer is one or more layers; The active component of each layer of drug-loaded layer is identical or different.
The invention provides a kind of intracranial bracket for eluting medicament, cilostazol Drug delivery is in support, support is implanted after lesion locations, supporting structure may provide advantage for the formation of microthrombus, and insert rear 5-7 days included wall thrombosis and peak, and, support after expansion embeds blood vessel wall, blood vessel wall is produced and continues to stimulate and damage, and therefore tunica intima produces neointimal hyperplasia reaction, and the reconstruct that blood vessel wall occurs thereupon makes to occur restenosis in the blood vessel of therapentic part.Support carries cilostazol medicine, at the local release of lesion, performance antiplatelet; vasodilation, suppresses vascular smooth muscle cell growth, suppresses thrombosis; the effects such as protection blood vessel wall and endotheliocyte and neuroprotective, thus prevent that tunica intima hyperplasia from causing the restenosis of blood vessel.
The present invention compared with prior art has following beneficial effect:
1. protection blood vessel and inflammation-inhibiting reaction;
2. reach and prevent intracranial vessel in-stent restenosis;
3. blood vessel dilating function.
Brief description of the drawings
Fig. 1 is intracranial bracket for eluting medicament induction system structure chart;
Fig. 2 is intracranial bracket for eluting medicament one deck drug-loaded layer;
Fig. 3 is the multilayer drug-loaded layer of intracranial bracket for eluting medicament.
In figure:
Medicine 3, support matrix 4, one deck drug-loaded layer 5 and multilayer drug-loaded layer 6 that induction system 1, support 2, support carry.
Detailed description of the invention
Below by the drawings and specific embodiments, content of the present invention is further described:
Specific implementation method:
By adopting conventional bracket for eluting medicament manufacture method, take attached drug-loaded layer in support.Drug-loaded layer comprises active component.Described active component is cilostazol.Bracket for eluting medicament reaches lesion locations, after support expansion, prevents the restenosis in support by the active ingredient cilostazol of drug-loaded layer.Cilostazol is by suppressing phosphodiesterase 3, thereby the concentration of increase cyclic adenosine monophosphate reaches the effect of anticoagulant.Simultaneously, cilostazol has protective effect to blood vessel, its mechanism of action is as follows: 1) by promoting the activity of eNOS (eNOS), (NO is important vasodilator to rising nitric oxide (NO) concentration, can improve microcirculation, safeguarding vascular endothelial function, constructing in vascular homeostasis process and play an important role); 2) suppress biologically active pdgf, antithrombotic forms; 3) expression of inflammation-inhibiting medium (cytokine MCP-1, PDGF, TNF-α, adhesion molecule VCAM-1 etc.), avoids blood vessel endothelium inflammatory damage; 4) suppress monocytic and migrate, propagation (monocytic migrating, adhering to blood vessel and penetrating interior subcutaneous formation foam cell is atherosclerotic early lesion, suppresses this process and can protect endothelium, suppresses atherosclerosis).In addition, cilostazol, as selectivity phosphodiesterase iii inhibitor, can suppress phosphodiesterase iii in vascular smooth muscle, rising cAMP concentration, thus blood vessel dilating improves blood flow.Cilostazol is the first strong antiplatelet drug with blood vessel dilating effect in the world.Its mechanism of action is as follows: 1) exciting cAMP dependent protein enzyme, and this enzyme activates sarcolemmic calcium ion pump, causes calcium efflux, and intracellular calcium level declines, thus blood vessel dilating smooth muscle, vasodilator; 2) activate sodium/potassium ATP enzyme, promote efflux of K+ ions, cause film hyperpolarization, voltage dependent channel on film is closed, flow of calcium ions reduces, thus vasodilator; 3) dephosphorylation of enhancing myosin light chain kinase, because myosin light chain phosphorylation can make actomyosin be activated myosin ATPase, thereby causes smooth muscle contraction, removes the expansible vascular smooth muscle of Phosphation so strengthen.
It is emphasized that; below be only preferred embodiment of the present invention; not the present invention is done to any pro forma restriction; any amendment simply, equivalent variations and modification that every foundation technical spirit of the present invention is done above embodiment, all still belong in the protection domain of technical solution of the present invention.
Claims (3)
1. an intracranial bracket for eluting medicament, comprise induction system, support and drug-loaded layer, it is characterized in that: described intracranial bracket for eluting medicament surface is with drug-loaded layer, drug-loaded layer is made up of polymer and active component, described active component is antiplatelet drug cilostazol, described polymer is ethylene-vinyl alcohol copolymer or vinyl-vinyl acetate copolymer or styrene-isobutylene block copolymer, the weight proportion of drug-loaded layer: polymer is 5-50%, and all the other are active component.
2. according to the intracranial bracket for eluting medicament described in right 1, it is characterized in that: described drug-loaded layer is one or more layers.
3. according to the intracranial bracket for eluting medicament described in right 1, it is characterized in that: the active component of each layer of drug-loaded layer is identical or different.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410184710.4A CN103948458A (en) | 2014-05-05 | 2014-05-05 | Encephalic drug eluting stent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410184710.4A CN103948458A (en) | 2014-05-05 | 2014-05-05 | Encephalic drug eluting stent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103948458A true CN103948458A (en) | 2014-07-30 |
Family
ID=51325914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410184710.4A Pending CN103948458A (en) | 2014-05-05 | 2014-05-05 | Encephalic drug eluting stent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103948458A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190008996A1 (en) * | 2016-01-08 | 2019-01-10 | Lifetech Scientific (Shenzhen) Co., Ltd. | Implanted Device |
| CN114051417A (en) * | 2019-07-09 | 2022-02-15 | 大塚医疗器械有限公司 | Drug dissolution type stent |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070098753A1 (en) * | 2005-10-27 | 2007-05-03 | Robert Falotico | Local administration of a combination of rapamycin and cilostazol for the treatment of vascular disease |
| CN103536971A (en) * | 2012-07-12 | 2014-01-29 | 赛诺医疗科学技术有限公司 | Drug eluting medical appliance capable of controllably releasing drugs and preparation method thereof |
| CN103566415A (en) * | 2012-08-02 | 2014-02-12 | 上海微创医疗器械（集团）有限公司 | Human body blood vessel implant with coatings on two surfaces and manufacturing method thereof |
| CN203829101U (en) * | 2014-05-05 | 2014-09-17 | 加奇生物科技(上海)有限公司 | Intracranial drug eluting stent |
-
2014
- 2014-05-05 CN CN201410184710.4A patent/CN103948458A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070098753A1 (en) * | 2005-10-27 | 2007-05-03 | Robert Falotico | Local administration of a combination of rapamycin and cilostazol for the treatment of vascular disease |
| CN103536971A (en) * | 2012-07-12 | 2014-01-29 | 赛诺医疗科学技术有限公司 | Drug eluting medical appliance capable of controllably releasing drugs and preparation method thereof |
| CN103566415A (en) * | 2012-08-02 | 2014-02-12 | 上海微创医疗器械（集团）有限公司 | Human body blood vessel implant with coatings on two surfaces and manufacturing method thereof |
| CN203829101U (en) * | 2014-05-05 | 2014-09-17 | 加奇生物科技(上海)有限公司 | Intracranial drug eluting stent |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190008996A1 (en) * | 2016-01-08 | 2019-01-10 | Lifetech Scientific (Shenzhen) Co., Ltd. | Implanted Device |
| US10799612B2 (en) * | 2016-01-08 | 2020-10-13 | Lifetech Scientific (Shenzhen) Co. Ltd. | Implanted device |
| CN114051417A (en) * | 2019-07-09 | 2022-02-15 | 大塚医疗器械有限公司 | Drug dissolution type stent |
| US11806257B2 (en) | 2019-07-09 | 2023-11-07 | Otsuka Medical Devices Co., Ltd. | Drug-eluting stent including crystalline cilostazol |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN203829101U (en) | Intracranial drug eluting stent | |
| Hausenloy et al. | Targeting myocardial reperfusion injury—the search continues | |
| Angiolillo et al. | Basic principles of platelet biology and clinical implications | |
| Shi et al. | Endogenous cardioprotection by ischaemic postconditioning and remote conditioning | |
| Gottsauner‐Wolf et al. | Restenosis—an open file | |
| WO2003037220A1 (en) | Improved endoprosthetic device | |
| Kaneko et al. | Anticoagulation for prosthetic valves | |
| CN101365447A (en) | Pharmaceuticals compositions containing nanomaterials useful for treating restenotic lesions | |
| Tanguay et al. | Prevention of in-stent restenosis via reduction of thrombo-inflammatory reactions with recombinant P-selectin glycoprotein ligand-1 | |
| Tesfamariam | Local arterial wall drug delivery using balloon catheter system | |
| CN102860890B (en) | Composite medicine carrying vessel stent and preparation method thereof | |
| MX2014003216A (en) | Controlled dosing of clopidogrel with gastric acid inhibition therapies. | |
| WO2007118131A3 (en) | Methods and devices for reducing tissue damage after ischemic injury | |
| CN103948458A (en) | Encephalic drug eluting stent | |
| De Gregorio et al. | Retrievability of uncoated versus paclitaxel-coated Günther-Tulip IVC filters in an animal model | |
| CN101130115A (en) | Drug eluting stent and therapeutic methods using C-JUN N-terminal kinase inhibitor | |
| CN101195048A (en) | Compound medicament washing bracket and method for preparing the same | |
| Park et al. | Effect of imatinib mesylate and rapamycin on the preformed intimal hyperplasia in rat carotid injury model | |
| CN101496813A (en) | Anti-hyperblastosis (vascular restenosis) composition and application method | |
| US20060222627A1 (en) | Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue | |
| Gomes et al. | Evaluation of the effect of allopurinol as a protective factor in post ischemia and reperfusion inflammation in Wistar rats | |
| Shen et al. | Nine-month angiographic and two-year clinical follow-up of novel biodegradable-polymer arsenic trioxide-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease | |
| JP2009521961A (en) | Coronary stent releasing drug composition for restenosis prevention treatment and its assembly process | |
| Abd-Elfattah et al. | Hot shot induction and reperfusion with a specific blocker of the es-ENT1 nucleoside transporter before and after hypothermic cardioplegia abolishes myocardial stunning in acutely ischemic hearts despite metabolic derangement: Hot shot drug delivery before hypothermic cardioplegia | |
| Chitkara et al. | Second versus first-generation drug-eluting stents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140730 |